Novartis Pharmaceuticals UK, Sandimmun Oral Solution
- The problem
- Novartis Pharmaceuticals UK are recalling a batch of Sandimmun Oral Solution due to the presence of crystals in the solution.
- What to do
- Check the batch number on your pack against the list below. Do not stop taking a prescribed medicine without talking to your pharmacist, GP or prescriber first – they can check your supply and swap it if needed.
MDR number
MDR 050-09/22
Company name
Novartis Pharmaceuticals UK
Product name
Sandimmun Oral Solution PL 00101/0124
| Batch number | Expiry date | Pack size | First distributed |
|---|---|---|---|
| ADP326002 | November 2024 | 50 ml | 06/05/2022 |
Active Pharmaceutical Ingredient: ciclosporin
Brief description of the problem
Novartis Pharmaceuticals UK are recalling the above batch due to the presence of crystals in the solution. The crystals have been identified as the active substance (ciclosporin). The presence of crystals has been observed in some finished product packs marketed in other countries that share the same master batch as the UK batch above. Therefore, this UK batch is recalled as a precautionary measure. Novartis Pharmaceuticals UK have confirmed no other batches of the product are impacted.
Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Advice for patients
- Patients should not stop taking Sandimmun Oral Solution without speaking to your doctor or other healthcare professionals, as stopping your treatment may increase the risk of your transplanted organ being rejected.
- The Marketing Authorisation Holder in the UK has not received any product complaints or adverse reactions related to the issue above. However, if you feel unwell whilst taking medicines from this batch then please seek urgent medical attention. Adverse reactions should also be reported via the MHRA Yellow Card scheme.
- If you have any questions about your Sandimmun Oral Solution or observe crystallised particles in the solution, talk to your pharmacist, transplant team or other healthcare professionals for advice.
Further Information
For more information, medical or supply enquiries, please contact 01276 698370, or email medinfo.uk@novartis.com
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Yours faithfully
Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
Download documents
Class 2 Medicines Recall: Novartis Pharmaceuticals UK, Sandimmun Oral Solution, EL(22)A/40
Updated 20 September 2022. This page summarises an official notice. Details can change – always follow the official notice.